Targeting IL-4 for the Treatment of Atopic Dermatitis

被引：0
|
作者：
Chiricozzi, Andrea [1 ,2 ]
Maurelli, Martina [3 ]
Peris, Ketty [1 ,2 ]
Girolomoni, Giampiero [3 ]
机构：
[1] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Dermatol, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dermatol, Rome, Italy
[3] Univ Verona, Dept Med, Sect Dermatol, Verona, Italy
来源：
IMMUNOTARGETS AND THERAPY | 2020年 / 9卷
关键词：
atopic dermatitis; IL-4; inhibitor; dupilumab; pascolizumab; pitrakinra; TH2; CYTOKINES; STAPHYLOCOCCUS-AUREUS; DERMAL FIBROBLASTS; DENDRITIC CELLS; TRANSGENIC MICE; LESIONAL SKIN; UP-REGULATION; IFN-GAMMA; IN-VITRO; T-CELLS;
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.
引用
收藏
页码：151 / 156
页数：6
相关论文
共 50 条
  • [1] The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis
    Pappa, Georgia
    Sgouros, Dimitrios
    Theodoropoulos, Konstantinos
    Kanelleas, Antonios
    Bozi, Evangelia
    Gregoriou, Stamatios
    Krasagakis, Konstantinos
    Katoulis, Alexander C.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (19)
  • [2] The IL-4, IL-13 and IL-31 pathways in atopic dermatitis
    Dubin, Celina
    Del Duca, Ester
    Guttman-Yassky, Emma
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (08) : 835 - 852
  • [3] IL-4 and IL-13 Inhibition in Atopic Dermatitis
    Matsunaga, Matthew C.
    Yamauchi, Paul S.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (08) : 925 - 929
  • [4] New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines
    Renert-Yuval, Yael
    Guttman-Yassky, Emma
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 124 (01) : 28 - 35
  • [5] Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach
    Di Lernia, Vito
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (01) : 87 - 96
  • [6] A molecular mechanism for IL-4 suppression of loricrin transcription in epidermal keratinocytes: implication for atopic dermatitis pathogenesis
    Bao, Lei
    Mohan, Girish C.
    Alexander, Jaime B.
    Doo, Caroline
    Shen, Kui
    Bao, Jeremy
    Chan, Lawrence S.
    INNATE IMMUNITY, 2017, 23 (08) : 641 - 647
  • [7] Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
    Calabrese, Laura
    D'Onghia, Martina
    Lazzeri, Laura
    Rubegni, Giovanni
    Cinotti, Elisa
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (07):
  • [8] Association of polymorphisms in genes encoding IL-4, IL-13 and their receptors with atopic dermatitis in a Korean population
    Namkung, Jung-Hyun
    Lee, Jong-Eun
    Kim, Eugene
    Kim, Hyun-Je
    Seo, Eun-Young
    Jang, Hye-Yoon
    Shin, Eun-Soon
    Cho, Eun-Young
    Yang, Jun-Mo
    EXPERIMENTAL DERMATOLOGY, 2011, 20 (11) : 915 - 919
  • [9] The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis
    Silverberg, Jonathan I.
    Kantor, Robert
    DERMATOLOGIC CLINICS, 2017, 35 (03) : 327 - +
  • [10] Exploring the Potential of IL-4 and IL-13 Plasma Levels as Biomarkers in Atopic Dermatitis
    Mitroi, George G.
    Plesea, Elena Leocadia
    Mitroi, George F.
    Mitroi, Mihaela Roxana
    Neagoe, Carmen Daniela
    Ianosi, Simona Laura
    LIFE-BASEL, 2024, 14 (03):
12345